Twist continues to believe that Agilent’s claims lack merit and that Agilent is not entitled to any relief. Twist is leveraging its unique technology to manufacture a broad range of synthetic DNA-based products, including synthetic genes, tools for next-generation sequencing (NGS) preparation, and antibody libraries for drug discovery and development. Twist Bioscience Partners with Invetx to Deliver Best-in-Class Antibody Therapeutics for Dogs and Cats Business Wire 07/16 08:00 ET Twist Bioscience Customer Vanderbilt University Medical Center (VUMC) Announces Publication of Positive Preclinical Results on Neutralizing Antibodies as a Potential Therapy for Preventing and Treating COVID-19
as Exhibit 99.1 and is incorporated into this Item 7.01 by reference. The defendants opposed both motions. On September 28, 2018, Agilent filed a motion for protective order seeking to impose limits on the defendants discovery in Twist is also pursuing longer-term opportunities in digital data storage in DNA and biologics drug discovery. ... we view Twist Bioscience as having one of the worst risk rewards in the public market. growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange been pending for several weeks. Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this Twist Bioscience Corporation (the Company) is party to a lawsuit filed on February 3, 2016, against the Company and its Chief Executive Officer, Ms. Emily Leproust, in the Superior Court of California, Santa Clara County (the Any forward-looking statements contained in this press release speak only as of the date hereof, and Twist Bioscience specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise.
Twist continues to believe Twist Bioscience Yesterday at 7:15 AM As part of # COVID19 webinar series, Biotech Connection Singapore hos ... ted speakers from academic and industry settings to discuss advances in the research community under the new ‘norm’, as well as the research efforts undertaken in facilitating basic and translational research in the fight against #SARSCoV2. Act. any of the new allegations or claims that Agilent seeks to add to the case. ☒ As previously disclosed, is inherently uncertain and there can be no assurance that the outcome of the case or the costs of litigation, regardless of outcome, will not have a material adverse effect on the Companys business. Under the terms of the agreement, which is legally binding, Twist Bioscience will pay Agilent $22.5 million. Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section, nor shall it be deemed to be incorporated by reference into any registration statement or other document filed pursuant to
of its motion to amend, which attached a new, proposed Second Amended Complaint that revised certain allegations. The Company posted a statement regarding the litigation update on the investor relations section of its website. All statements other than statements of historical facts contained herein are forward-looking statements reflecting the current beliefs and expectations of management made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Court) by Agilent Technologies, Inc. (Agilent). Twist Bioscience is a leading and rapidly growing synthetic biology company that has developed a disruptive DNA synthesis platform to industrialize the engineering of biology. The Company intends to use the investor relations section of its website as a means of complying with its disclosure obligations under Regulation FD. In so ruling, the Court did not address the merits of This press release contains forward-looking statements. Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA, today announc Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to Twist Bioscience’s business in general, see Twist Bioscience’s risk factors set forth in Twist Bioscience’s Annual Report on Form 10-K filed with the Securities and Exchange Commission on December 13, 2019.